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Abstract 
 
Current treatment options for neuroblastoma fail to eradicate the disease in the majority 
of high-risk patients, clearly mandating development of innovative therapeutic strategies. 
Gene therapy represents a promising approach for reversing the neoplastic phenotype or 
driving tumor cells to self-destruction. We presently studied the effects of adenovirus-
mediated gene transfer of human polynucleotide phosphorylase (hPNPase
old-35
), a 3′,5′-
exoribonuclease with growth-inhibitory properties, in neuroblastoma cells. Transgene 
expression was driven by either the cytomegalovirus (CMV) promoter or by a tumor-
selective promoter derived from Progression Elevated Gene-3 (PEG-3). Our data 
demonstrate that efficient adenoviral transduction of neuroblastoma cells and robust 
transgene expression are feasible objectives, that the PEG-3 promoter is capable of 
selectively targeting gene expression in the majority of neuroblastoma cells, and that 
hPNPase
old-35
 induces profound growth suppression and apoptosis of malignant 
neuroblastoma cells, while exerting limited effects on normal neural crest-derived 
melanocytes. These findings support future applications of hPNPase
old-35
 for targeted 
gene-based therapy of neuroblastoma and suggest that combination with the PEG-3 
promoter holds promise for creating a potent and selective neuroblastoma therapeutic. 
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Introduction 
 
Successful treatment of high-risk neuroblastoma remains a major challenge in pediatric 
oncology. This neural crest-derived malignancy accounts for approximately 15% of all 
childhood cancer mortality in the US (Maris et al., 2007). Clinical and biological 
characteristics, such as age at diagnosis, disease stage, histopathology, tumor cell DNA 
content (ploidy), and copy number status of the N-myc oncogene, allow for stratification 
of neuroblastoma patients into different risk groups (Brodeur, 2003; Maris et al., 2007). 
About half of all cases are currently classified as high-risk disease, with a mortality rate 
exceeding 60%, pointing at a compelling need to develop alternative treatment strategies 
(Maris et al., 2007). 
 
An intriguing therapeutic opportunity for a number of human diseases may be offered by 
a group of ribonucleases endowed with cytotoxic, immunosuppressive, antitumor, 
angiogenic, and aspermatogenic activities. These enzymes are referred to as 
Ribonucleases with Special Biological Actions or RISBASEs (D'Alessio, 1993), as their 
functions extend beyond the processing and turnover of cellular RNA and the breakdown 
of dietary RNA. Such specialized ribonucleases are present from prokaryotes to higher 
mammals and operate in a variety of biological processes, including interstrain 
competition in bacteria, prevention of self-pollination in plants, pathogen survival within 
host tissues, antiparasitic, antifungal and antiviral defense, neovascularization, and 
antitumor action (D'Alessio, 1993; Youle et al., 1993). Interestingly, two of the best-
studied antitumor ribonucleases, onconase and bovine seminal ribonuclease, have shown 
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profound activity against neuroblastoma both in vitro and in vivo, even in a context of 
resistance to conventional chemotherapeutic agents (Cinatl et al., 1999, 2000; Kotchetkov 
et al., 2000; Michaelis et al., 2007). The molecular basis underlying the cytotoxicity of 
these ribonucleases is not fully understood, but it is accepted that this activity requires 
interaction with the cell membrane, internalization by endocytosis, translocation to the 
cytosol, resistance to the endogenous ribonuclease inhibitor (RI) in the cytosol as well as 
to extracellular and intracellular proteases, and cleavage of cellular RNA (Benito et al., 
2005; Arnold and Ulbrich-Hofmann, 2006). Onconase is the only ribonuclease hitherto 
evaluated in clinical trials, with promising results (Beck et al., 2008), although some 
caution is warranted in view of a relatively high renal uptake compared to other 
ribonucleases (Vasandani et al., 1996) and evidence of acute multifocal proximal renal 
tubular necrosis in mice treated with onconase (Vasandani et al., 1999). 
 
We previously identified an evolutionary conserved 3′,5′-exoribonuclease, human 
polynucleotide phosphorylase (hPNPase
old-35
), in an overlapping-pathway screen (OPS) 
aimed at delineation of genes displaying coordinated changes in expression during 
terminal differentiation of human melanoma cells and cellular senescence of progeroid 
fibroblasts (Leszczyniecka et al., 2002). Overexpression of hPNPase
old-35
 in both 
processes suggested implication in regulation of cellular growth, and subsequent studies 
documented a potent and widely applicable growth-inhibitory activity. hPNPase
old-35
 is 
an early IFN-α/β response gene (Leszczyniecka et al., 2002, 2003), and has been shown 
to play a pivotal role in IFN-β-induced growth inhibition by a remarkable ability to 
specifically degrade c-myc mRNA (Sarkar et al., 2006). Transduction of normal human 
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melanocytes with an hPNPase
old-35
-encoding non-replicating adenovirus induces a 
growth arrest with distinctive morphological and biochemical characteristics of 
senescence (Sarkar and Fisher, 2006). In melanoma cells, adenoviral overexpression of 
hPNPase
old-35
 not only provokes a G1 cell cycle arrest and senescence, but also a 
pronounced degree of apoptosis (Sarkar et al., 2003). The growth-suppressive effect of 
hPNPase
old-35
 was similarly observed in breast, colon, prostate and pancreatic carcinoma, 
glioblastoma multiforme, fibrosarcoma, and osteosarcoma (Sarkar et al., 2003; and data 
not shown). Upregulation of hPNPase
old-35
 might also mediate chronic inflammatory 
pathological processes during aging (Sarkar et al., 2004). The RNase PH (RPH) domains 
of hPNPase
old-35
 are critical in mediating its phenotypic effects (Sarkar et al., 2005). 
Multiple molecular mechanisms seem to play a role in the growth-inhibitory and 
proinflammatory activity, including selective degradation of c-myc mRNA (Sarkar et al., 
2003, 2006), activation of double-stranded RNA-dependent protein kinase (PKR) (Sarkar 
et al., 2007), and generation of reactive oxygen species with subsequent NF-κB activation 
(Sarkar et al., 2004). 
 
The present study explores if hPNPase
old-35
 could be exploited as a selective and 
efficacious tool for gene therapy of neuroblastoma. This strategy was pursued using 
replication-incompetent adenoviruses in which hPNPase
old-35
 expression is driven by the 
CMV minimal promoter (Ad.CMV-hPNPase
old-35
) or by the minimal promoter region of 
Progression Elevated Gene-3, PEG-3 (Ad.PEG-hPNPase
old-35
). The PEG-3 promoter was 
found previously to function selectively in diverse cancer cells with limited activity in 
normal cells, and hence has the potential of cancer-specific targeting of transgene 
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expression (Su et al., 2005). Our results lend support to the potential use of adenovirus-
based hPNPase
old-35
 delivery in the treatment of neuroblastoma. 
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Materials and Methods 
 
Cell lines and culture conditions 
Human neuroblastoma cell lines IMR-32, NGP, SHEP and SK-N-SH were kindly 
provided by Dr. R. Versteeg (University of Amsterdam, The Netherlands), and SK-N-
BE(2c) human neuroblastoma cells by Dr. J. Lunec (University of Newcastle, UK). 
Human DU-145 prostate carcinoma cells were purchased from the American Type 
Culture Collection (Manassas, VA). An SV40 T-antigen immortalized human foreskin 
melanocyte cell line, FM-516-SV, was initially provided by Dr. L. Diamond (Wistar 
Institute, PA). The present studies used a subclone of FM-516-SV cells (Sarkar et al., 
2006). All cells were cultured as described (Van Maerken et al., 2006). 
 
Adenoviral vector construction, virus production and infection protocol 
The recombinant replication-defective adenoviruses, Ad.CMV-GFP (green fluorescence 
protein [GFP] expression driven by CMV promoter), Ad.CMV-hPNPase
old-35
 
(hemagglutinin [HA]-tagged hPNPase
old-35
 expression driven by CMV promoter), and 
Ad.PEG-hPNPase
old-35
 (HA-tagged hPNPase
old-35
 expression driven by PEG-3 promoter), 
were created by cloning the transgene into a shuttle vector followed by homologous 
recombination in E. coli of the shuttle vector with an adenoviral vector in which the E1 
and E3 regions have been deleted, as described previously (Leszczyniecka et al., 2002; 
Holmes et al., 2003). Production of viral particles in HEK293 cells, virus purification, 
and titration were performed as described (Holmes et al., 2003). Adenoviral infection of 
cells, 24 h after plating, was performed at the indicated multiplicity of infection (MOI) in 
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a minimal volume of serum-free RPMI 1640 medium for 3 h at 37 °C, with rocking of 
the plates every 15 min, followed by replenishment of complete medium and incubation 
at 37 °C for the indicated times. The empty adenoviral vector, Ad.vec, was used as a 
control. 
 
Flow cytometric analysis of GFP expression 
Cells were seeded in 6-well plates (2.5 × 10
5
 cells per well), incubated for 24 h, and 
infected with Ad.CMV-GFP at an MOI of 0, 12.5, 25, 50, 100 or 200 plaque-forming 
units (pfu) per cell. After 24 h, cells were harvested by trypsinization, washed with 
phosphate-buffered saline (PBS), and analyzed for the expression of GFP on a 
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) equipped with CellQuest 
Pro acquisition and analysis software version 5.2 (BD Biosciences). The percentage of 
GFP-positive cells was quantified using FlowJo version 8.5.3 for Macintosh (Tree Star, 
Ashland, OR). 
 
Detection of coxsackie-adenovirus receptors (CAR) on the cell surface 
Quantification of surface expression of CAR was performed as described previously 
(Lebedeva et al., 2002). Briefly, cells were incubated with mouse monoclonal anti-CAR 
antibody for 1 h at 37 °C (1:1000 dilution; Millipore, Billerica, MA), washed, exposed to 
fluorescein isothiocyanate (FITC)-conjugated anti-mouse immunoglobulins (1:1000 
dilution; Sigma, St. Louis, MO) for 1 h at 37 °C in the dark, washed again, and analyzed 
on a FACSCalibur using CellQuest Pro version 5.2 (BD Biosciences). Unstained cells, 
cells stained with secondary antibody only, and cells incubated with isotype control 
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primary antibody followed by secondary antibody were used as controls. Acquired data 
were analyzed in FlowJo version 8.5.3 for Macintosh (Tree Star) using two evaluation 
methods. The peak shift was calculated as the difference in peak channels between the 
cells stained with anti-CAR antibody and the control cells with the highest FITC signal 
intensity, relative to the position of the peak channel of these control cells. The second 
method used the Kolmogorov-Smirnov two-sample test for analysis of the flow 
cytometric histograms (Young, 1977). This test computes, starting from the histograms, 
the cumulative distribution function of fluorescence intensity for each sample and 
determines the difference between the cumulative distribution functions, with the D value 
indicating the greatest difference between the two curves. 
 
Analysis of the number of viable cells 
Cells were seeded in 96-well tissue culture plates (5 × 10
3
 cells per well), incubated for 
24 h, and infected in quadruplicate wells with different adenoviruses at 100 pfu/cell. At 1, 
3 and 5 days postinfection, the medium was carefully replaced by fresh medium 
containing 0.5 mg/mL MTT (Calbiochem, San Diego, CA), followed by incubation of the 
cells at 37 °C for 4 h and then addition of an equal volume of solubilization solution 
(0.01 HCl in 10% sodium dodecyl sulfate [SDS]) to each well. The absorbance of the 
wells was read at 595 nm with a Bio-Rad Model 550 microplate reader (Bio-Rad, 
Hercules, CA). Each condition was tested in three independent experiments. 
 
Cell cycle and hypodiploidy analysis 
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Cells were plated in 10-cm dishes (1 × 10
6
 cells per dish) and infected the next day with 
different adenoviruses at 100 pfu/cell. Measurement of cell cycle phase distribution and 
hypodiploid DNA content was performed at 2, 3, 4 and 5 days postinfection. Cells were 
trypsinized, washed 2 × with PBS, and fixed in 70% ethanol overnight at –20 °C. The 
cells were subsequently washed 2 × with PBS, treated with 0.5 mg/mL RNase A at 37 °C 
for 30 min, and incubated with 0.1 mg/mL propidium iodide at room temperature for 30 
min. Cellular DNA content was measured with a FACSCalibur using CellQuest Pro 
version 5.2 (BD Biosciences). Cell cycle fractions and the apoptotic A0 population were 
quantified using FlowJo version 8.5.3 for Macintosh (Tree Star). 
 
Analysis of caspase-3 and caspase-7 activity 
Cells were seeded in 96-well tissue culture plates (5 × 10
3
 cells per well), incubated for 
24 h, and infected in triplicate wells with different adenoviruses at 100 pfu/cell. The 
combined activity of caspase-3 and caspase-7 was measured at 2 and 3 days postinfection 
using the Caspase-Glo 3/7 assay (Promega, Madison, WI) and a Modulus microplate 
luminometer (Turner BioSystems, Sunnyvale, CA). 
 
Western blot analysis 
Protein lysates were prepared on ice in RIPA buffer (Sigma) containing protease and 
phosphatase inhibitor cocktails (Roche, Mannheim, Germany), and clarified by 
centrifugation at 16,000 × g for 15 min at 4 °C. Protein concentrations were determined 
using the Bradford assay (Bio-Rad). Aliquots containing 25 µg of total protein were 
resolved by electrophoresis on 8% SDS-polyacrylamide gels, transferred to 0.2 µm 
Page 11 of 40
John Wiley & Sons, Inc.
Journal of Cellular Physiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 12 
nitrocellulose membranes (Pall Corporation, East Hills, NY), and probed with mouse 
monoclonal antibodies against HA (1:2000 dilution; Covance, Berkeley, CA) and EF1α 
(1:1000 dilution; Millipore). Horseradish peroxidase (HRP)-conjugated goat anti-mouse 
immunoglobulins (1:5000 dilution; Sigma) were used as secondary antibodies. Bands 
were visualized using ECL Plus detection reagents (Amersham Biosciences, Piscataway, 
NJ) according to the manufacturer’s instructions. 
 
Real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen, Valencia, CA), 
with RNase-free DNase I treatment on column. After an additional RQ1 DNase treatment 
in solution (Promega), first-strand cDNA was synthesized from 2 µg total RNA using the 
iScript cDNA synthesis kit (Bio-Rad). Relative mRNA expression levels were 
determined using an optimized two-step SYBR Green I real-time quantitative RT-PCR 
assay with minor modifications (Vandesompele et al., 2002a). Primer sequences are 
available in the public RTPrimerDB database (http://medgen.ugent.be/rtprimerdb/) 
(Pattyn et al., 2003, 2006): GAPDH [RTPrimerDB ID 3], SDHA [7], UBC [8], NEFH 
[3504], NEFL [3505], NEFM [3507], and CHAT [3502]. The PCR was run on a 
LightCycler 480 instrument (Roche) in duplicate reactions of 7.5 µL, containing 250 nM 
of each primer and cDNA equivalent to 20 ng of total RNA. Gene expression levels and 
PCR efficiency, along with its standard error, were calculated using qBasePlus 1.0 
analysis software (http://www.biogazelle.com) (Hellemans et al., 2007), which employs a 
delta-Ct relative quantification model with PCR efficiency correction and multiple 
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reference gene normalization (Vandesompele et al., 2002b). Expression levels of GAPDH, 
SDHA and UBC were used for normalization. 
Page 13 of 40
John Wiley & Sons, Inc.
Journal of Cellular Physiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 14 
Results 
 
Adenoviral transduction efficiency of neuroblastoma cells and expression of 
coxsackie-adenovirus receptors (CAR) on the cell surface 
To determine the infectivity of neuroblastoma cells by adenoviral vectors and the 
efficiency of transgene expression, cells were infected with a recombinant replication-
defective adenovirus expressing GFP under control of the CMV promoter (Ad.CMV-
GFP) at various MOIs (ranging from 12.5 to 200 pfu/cell) and monitored for the 
expression of GFP 24 h postinfection using flow cytometry. Transduction efficiency was 
assessed by calculating the percentage of cells expressing GFP. This analysis was 
performed on five human neuroblastoma cell lines [IMR-32, NGP, SHEP, SK-N-BE(2c), 
and SK-N-SH], on normal human melanocytes immortalized by SV40 T-antigen (FM-
516-SV), and on human DU-145 prostate carcinoma cells. The immortalized melanocytes 
were chosen as a reference point in this study, as they share a common embryonic origin 
with neuroblastoma cells and as the exact normal counterparts for this malignancy, 
human fetal neuroblasts, are not available due to ethical and technical considerations. The 
DU-145 cells were included as a positive control, since these cells are characterized by a 
high level of surface expression of CAR proteins, which mediate adenovirus attachment 
and uptake in cells, and accordingly by an excellent adenoviral infectivity (Lebedeva et 
al., 2003). As shown in Figure 1, the adenoviral transduction efficiency of neuroblastoma 
cells was MOI-dependent and comparable to that obtained with the DU-145 prostate 
carcinoma cells. At an MOI of 200 pfu/cell, transduction efficiency ranged from 62% to 
88% for neuroblastoma cells [percentage of cells positive for GFP expression: SK-N-
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BE(2c), 62%; NGP, 63%; IMR-32, 66%; SK-N-SH, 86%; SHEP, 88%] and was 83% for 
DU-145 cells. A slightly lower transduction efficiency was recorded for FM-516-SV 
immortalized melanocytes (55% of cells positive for GFP expression at 200 pfu/cell). 
 
We next investigated the expression of CAR on the cell surface by flow cytometry using 
monoclonal antibodies against CAR (Table 1). Surface expression of this receptor was 
detectable for all seven cell lines in this study, as evidenced by the Kolmogorov-Smirnov 
two-sample test for analysis of flow cytometric histograms (P<.001 for each cell line). 
Analysis of the peak shift in fluorescence signal after staining with anti-CAR antibody 
and FITC-conjugated secondary antibody indicated the following order of surface CAR 
number and availability: DU-145 > IMR-32 > NGP > SHEP > SK-N-SH > SK-N-BE(2c) 
> FM-516-SV. Based on these results, it is obvious that a simple correlative relationship 
does not exist between surface CAR levels and GFP expression after exposure of cells to 
Ad.CMV-GFP, suggesting a differential regulation of transgene expression after virus 
entry. 
 
Taken together, these data indicate that efficient adenoviral infection and transgene 
expression is achievable in neuroblastoma cells, and support the development of 
adenovirus-mediated gene therapy approaches for neuroblastoma. 
 
Expression of hPNPase
old-35
 in FM-516-SV and neuroblastoma cells following 
adenoviral gene transfer 
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For assessment of the therapeutic potential of adenovirus-based hPNPase
old-35
 delivery 
for the treatment of neuroblastoma, we decided to explore both the effects of a classical 
gene expression vector as well as of gene transfer under control of a promoter with 
cancer-specific properties. Previous studies in multiple tumor models, including human 
breast carcinoma, glioblastoma multiforme, pancreatic carcinoma and prostate cancer, 
demonstrated a significantly higher activity of the PEG-3 promoter in tumor cells 
compared to their normal counterparts (Su et al., 2005; Chan et al., 2008). We 
constructed two replication-incompetent adenoviruses, Ad.CMV-hPNPase
old-35
 and 
Ad.PEG-hPNPase
old-35
, in which hPNPase
old-35
 expression is driven by the CMV minimal 
promoter and by the minimal promoter region of PEG-3, respectively. The hPNPase
old-35
 
transgene was engineered to encode a hemagglutinin (HA)-tag at the COOH-terminus for 
monitoring expression. To determine the optimum MOI of Ad.CMV-hPNPase
old-35
 and 
Ad.PEG-hPNPase
old-35
 infection, neuroblastoma and FM-516-SV cells were infected at 
25, 50, 100 and 200 pfu/cell, and transgene expression was measured by Western blot 
analysis using an anti-HA antibody. The empty adenoviral vector, Ad.vec, was used as a 
control. 
 
As illustrated in Figure 2, infection with Ad.CMV-hPNPase
old-35
 induced an MOI-
dependent expression of hPNPase
old-35
 in both FM-516-SV immortalized melanocytes 
and neuroblastoma cells. In contrast, infection with Ad.PEG-hPNPase
old-35
 did not result 
in hPNPase
old-35
 expression in FM-516-SV cells, while the degree of transgene 
expression in neuroblastoma cells after incubation with this adenovirus was variable, 
ranging from weak HA bands in SHEP and SK-N-BE(2c) cells to a pronounced dose-
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dependent expression in IMR-32, NGP and SK-N-SH cells. These results validate the 
functionality of both constructed hPNPase
old-35
-encoding adenoviral vectors and 
demonstrate that the PEG-3 promoter is capable of selectively targeting gene expression 
in the majority of human neuroblastoma cells. We selected 100 pfu/cell as the optimal 
working concentration for further experiments, as infection with Ad.CMV-hPNPase
old-35
 
and Ad.PEG-hPNPase
old-35
 at 200 pfu/cell resulted in markedly rapid cell death. 
 
Selective growth suppression by Ad.CMV-hPNPase
old-35
 and Ad.PEG-hPNPase
old-35
 
in neuroblastoma cells 
We next addressed whether adenovirus-mediated hPNPase
old-35
 gene transfer could 
selectively inhibit the growth of neuroblastoma cells. We therefore infected FM-516-SV 
melanocytes and neuroblastoma cells with Ad.vec, Ad.CMV-hPNPase
old-35
 and Ad.PEG-
hPNPase
old-35
 at 100 pfu/cell, and monitored the number of viable cells by MTT assay at 
1, 3 and 5 days postinfection. As depicted in Figure 3, infection with Ad.CMV-
hPNPase
old-35
 and Ad.PEG-hPNPase
old-35
 resulted in a pronounced suppression of growth 
of IMR-32, NGP, SK-N-BE(2c) and SK-N-SH cells. These growth-inhibitory effects 
became apparent from 3 days after infection, and were most prominent at day 5. It should 
be noted that exposure to the empty adenoviral vector, Ad.vec, also resulted in some 
growth inhibition of these cells, but this effect was considerably smaller than the decrease 
in cell number induced by the hPNPase
old-35
-encoding adenoviruses [additional degree of 
growth suppression due to the transgene component, relative to the number of Ad.vec-
infected cells, at day 5 postinfection: 50-60% for IMR-32, NGP and SK-N-SH cells, and 
20-30% for SK-N-BE(2c) cells]. On the contrary, transduction of SHEP neuroblastoma 
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cells and FM-516-SV melanocytes with Ad.CMV-hPNPase
old-35
 and Ad.PEG-
hPNPase
old-35
 resulted in only a slight decrease in the number of viable cells at day 5 
postinfection. 
 
Taken together, these findings suggest that both Ad.CMV-hPNPase
old-35
 and Ad.PEG-
hPNPase
old-35
 have the ability to suppress the growth of most human neuroblastoma cells. 
The observation that infection with Ad.CMV-hPNPase
old-35
 exerted only a limited 
growth-inhibitory effect on FM-516-SV immortalized normal melanocytes, despite a 
distinct induction of hPNPase
old-35
 expression, supports the notion of hPNPase
old-35
 as a 
tumor-selective growth-suppressive gene and hence as a valuable gene therapy tool for 
the treatment of cancer. 
 
Effects of adenoviral infection and hPNPase
old-35
 expression on cell cycle progression, 
apoptosis, and neuronal differentiation of neuroblastoma cells 
To investigate the mechanism of growth inhibition, cellular effects of adenovirus-
mediated hPNPase
old-35
 expression were studied in detail in two well-responsive 
neuroblastoma cell types, NGP and SK-N-SH, and in the poorly responsive SHEP cells. 
Flow cytometric cell cycle profiling of NGP cells indicated that infection with Ad.CMV-
hPNPase
old-35
 and Ad.PEG-hPNPase
old-35
 at 100 pfu/cell resulted in a decrease of cells in 
the S phase, reflective of inhibition of DNA synthesis (Fig. 4A). At early timepoints after 
infection, this change was mainly accompanied by accumulation of NGP cells in the G1 
phase, while a gradual increase in the sub-G1 (A0) population of cells at day 4 and 5 
postinfection indicated the occurrence of apoptotic cell death. Infection of NGP cells with 
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Ad.vec at 100 pfu/cell induced a comparable G1 cell cycle arrest, but only a mild degree 
of apoptosis. The response of SK-N-SH cells to adenovirus-mediated hPNPase
old-35
 gene 
transfer was characterized by a more extensive and more rapid induction of apoptosis, as 
evidenced by the A0 fraction, with an initial arrest at the G1/S boundary still observable 
after Ad.PEG-hPNPase
old-35
 infection (Fig. 4B). The empty adenoviral vector, Ad.vec, 
also elicited an inhibition of the G1/S transition in SK-N-SH cells, but only a modest 
increase in hypodiploid DNA content. In contrast to the pronounced degree of apoptosis 
observed in NGP and SK-N-SH cells following Ad.CMV-hPNPase
old-35
 and Ad.PEG-
hPNPase
old-35
 infection, transduction of SHEP cells with these viruses resulted in only a 
limited increase in the A0 population, along with a slight G1 arrest (Fig. 4C). 
 
The induction of apoptosis by Ad.CMV-hPNPase
old-35
 and Ad.PEG-hPNPase
old-35
 
infection of NGP and SK-N-SH cells was confirmed by analysis of caspase-3 and 
caspase-7 activity (Fig. 5). Adenovirus-mediated hPNPase
old-35
 expression evoked a 2- to 
3-fold and a 3- to 5-fold increase in caspase-3 and caspase-7 activity in NGP and SK-N-
SH cells, respectively, measured 2-3 days after infection at 100 pfu/cell. No activation of 
these apoptotic effector enzymes was recorded in Ad.vec-infected NGP and SK-N-SH 
cells. Exposure of SHEP cells to Ad.CMV-hPNPase
old-35
 and Ad.PEG-hPNPase
old-35
 at 
100 pfu/cell did not induce caspase-3 and caspase-7 activity, in keeping with the limited 
growth-suppressive effects that were observed using MTT assays. 
 
Interestingly, microscopic evaluation of adenovirally infected NGP cells revealed striking 
morphological changes indicative of neuronal differentiation, such as the acquisition of a 
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bipolar or stellate appearance, and the formation of long neurites with varicosities and 
growth cone-like endings (Fig. 6A). These alterations were observed after infection of 
NGP cells with either of the evaluated adenoviruses (Ad.vec, Ad.CMV-hPNPase
old-35
, 
and Ad.PEG-hPNPase
old-35
), but not after transduction of any other cell type in this study. 
Confirmation of the neuronal differentiation process following adenoviral infection of 
NGP cells was obtained by expression analysis of neuronal differentiation markers using 
real-time quantitative RT-PCR (Fig. 6B). Adenoviral infection of NGP cells resulted in a 
marked increase in expression of the genes encoding the heavy, light, and medium 
neurofilament subunits (NEFH, NEFL, and NEFM, respectively) and of the rate-limiting 
enzyme in the biosynthesis of acetylcholine (CHAT), suggestive of differentiation along a 
cholinergic neuronal lineage. 
 
Collectively, these data demonstrate that adenoviral infection of neuroblastoma cells 
results in a G1 cell cycle arrest, which was accompanied by neuronal differentiation in 
NGP cells, that hPNPase
old-35
 expression triggers a pronounced apoptotic response in 
NGP and SK-N-SH cells, and that the limited growth-inhibitory activity of hPNPase
old-35
 
gene delivery in SHEP cells correlates with a lack of apoptosis induction. 
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Discussion 
 
The poor survival rates of high-risk neuroblastoma patients and the long-term severe side 
effects of current treatment regimens clearly warrant development of more effective and 
less toxic therapeutic modalities. Gene therapy holds great promise to improve the 
treatment of cancer, as gene transfer offers in principle the most direct and rational means 
to counteract the multiplicity of genetic events underlying the neoplastic process or to 
bring about destructi n or incapacitation of tumor cells. Efforts to develop gene 
therapeutic approaches for treatment of neuroblastoma have been relatively limited to 
date. The present study was undertaken to evaluate a promising growth-inhibitory gene, 
hPNPase
old-35
, operative through a mechanism completely different from those of 
conventional chemotherapeutic drugs, as a potential therapeutic agent for neuroblastoma, 
using adenovirus-mediated gene delivery with transgene expression driven by either the 
CMV promoter or by a cancer-selective promoter derived from the PEG-3 gene. Our 
findings support the concept that hPNPase
old-35
 is a negative regulator of growth and 
survival of neuroblastoma cells and that this gene may b  exploited for an adenovirus-
based gene therapy approach of neuroblastoma. 
 
A prerequisite for a successful therapeutic modality is selective activity in tumor cells 
with minimal damage to normal cells. FM-516-SV immortalized normal melanocytes, 
which are, similarly to neuroblastoma cells, embryonically derived from the neural crest, 
were only to a limited extent suppressed in their growth after infection with Ad.CMV-
hPNPase
old-35
, despite a clear induction of hPNPase
old-35
 expression. In contrast, most 
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neuroblastoma cell types showed pronounced growth inhibition after transduction with 
Ad.CMV-hPNPase
old-35
. As selective delivery of genes to cancer cells remains one of the 
major hurdles to clinical implementation of gene therapy approaches, we decided to 
combine the growth-inhibitory effect of hPNPase
old-35
 with the wide-ranging cancer-
selective activity of the PEG-3 promoter (Su et al., 2005). Use of the latter promoter 
induced a marked dose-dependent expression of hPNPase
old-35
 and a profound growth 
suppression in IMR-32, NGP and SK-N-SH neuroblastoma cells, suggesting eligibility of 
a substantial fraction f neuroblastoma cases for treatment with PEG-3 promoter-based 
gene therapy regimens. 
 
The precise mechanism of the cancer selectivity and resulting favorable therapeutic index 
of the various antitumor ribonucleases described thus far remains to be elucidated (Benito 
et al., 2005; Arnold and Ulbrich-Hofmann, 2006). With regard to hPNPase
old-35
, we 
previously documented its ability to selectively degrade c-myc mRNA as essential to the 
growth arrest induced by Ad.CMV-hPNPase
old-35
 infection or IFN-β treatment of 
melanoma cells (Sarkar et al., 2003, 2006). We therefore investigated whether 
hPNPase
old-35
 was also capable of specifically degrading N-myc mRNA in neuroblastoma 
cells, but this appears not to be the case (data not shown) and this would not have 
explained the excellent growth-inhibitory and proapoptotic activity of adenovirus-
mediated hPNPase
old-35
 gene transfer against the N-myc single-copy SK-N-SH cells. It is 
possible that a preferential degradation of other mRNA species encoding key proteins in 
neuroblastoma cell maintenance underlies the cytotoxic effect of hPNPase
old-35
 on 
neuroblastoma cells. Additional research to unravel determinants of the substrate 
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specificity of hPNPase
old-35
 activity will be needed to clarify this issue. Alternatively, it 
might be that malignant neuroblastoma cells are more dependent than normal cells on the 
overall integrity of their RNA due to their high proliferative and metabolic rate or due to 
collateral proapoptotic signals derived from the myriad of stresses to which tumor cells 
are subjected. Another explanation for the observed tumor selectivity of hPNPase
old-35
 
relates to the possibility of degradation of microRNAs (miRNAs), as has been postulated 
previously for other cytotoxic ribonucleases (Ardelt et al., 2003), since cumulating 
evidence indicates that miRNAs are deeply implicated in tumor biology but of 
considerably less importance in fully-developed normal cells. 
 
A more thorough understanding of the molecular mode of action of hPNPase
old-35
 might 
also shed light on the relatively resistant phenotype of SHEP cells. It is worth noting that 
these cells also have a poor response to irradiation (Jasty et al., 1998; Tweddle et al., 
2001) and to various cytotoxic agents (unpublished observations), pointing at a more 
general insensitivity of SHEP cells to certain cell death-inducing triggers. This might for 
instance be related to a yet undefined block on apoptotic effector pathways in SHEP cells 
(Jasty et al., 1998), but an alternative hypothesis involves the poor tumorigenicity of 
these cells. SHEP cells, although widely used in neuroblastoma research, do neither form 
colonies in soft agar nor tumors when injected in nude mice (Ross and Spengler, 2007), 
and hence it can be questioned whether these tumor-derived cells still represent true 
malignant cells. In such a scenario, it is not surprising that the response of SHEP cells to 
adenovirus-mediated hPNPase
old-35
 gene transfer resembles more closely the slight 
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growth suppression induced in FM-516-SV immortalized normal melanocytes than the 
strong apoptotic response of highly malignant neuroblastoma cells. 
 
Interestingly, the process of adenoviral infection was sufficient to induce neuronal 
differentiation of NGP cells. Neuroblastoma is thought to arise from precursor cells of the 
sympathoadrenal system that are arrested at a developmental stage prior to completion of 
lineage maturation (McConville and Forsyth, 2003). As such, it is not unexpected that the 
induction of cell cycle arrest by adenoviral infection, which was observed in all cell lines 
evaluated, might be coupled with resumption of execution of the differentiation program. 
The observation of adenovirus-induced neuronal differentiation of NGP cells is however 
of interest from a clinical perspective, as it opens the possibility that some neuroblastoma 
tumors may mature after treatment with an adenovirus-based gene therapy approach. 
 
In summary, our results indicate that hPNPase
old-35
 may have utility for gene-based 
therapy of neuroblastoma and that the PEG-3 promoter may provide a valuable tool for 
selective gene delivery to most neuroblastoma cells. Further studies in experimental 
animal models of neuroblastoma are essential to successfully translate this approach into 
a viable therapeutic strategy for neuroblastoma. 
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Figure legends 
 
Figure 1. Infection with Ad.CMV-GFP induces GFP expression in neuroblastoma cells. 
A panel of five human neuroblastoma cell lines [IMR-32, NGP, SHEP, SK-N-BE(2c), 
and SK-N-SH], DU-145 human prostate carcinoma cells, and FM-516-SV immortalized 
human melanocytes were infected with Ad.CMV-GFP at the indicated MOIs, and 
analyzed for the expression of GFP 24 h postinfection using flow cytometry. Columns 
represent the mean percentages of GFP-positive cells of three different experiments, and 
error bars indicate standard errors of the mean. Asterisk, percentage of GFP-positive cells 
24 h after mock infection ranged from 0.19% to 0.22% for all cell lines. 
 
Figure 2. Expression of hPNPase
old-35
 in FM-516-SV human melanocytes and 
neuroblastoma cells following adenoviral gene transfer. FM-516-SV immortalized 
melanocytes and a panel of five neuroblastoma cell lines were infected with Ad.vec, 
Ad.CMV-hPNPase (Ad.CMV-hPNPase
old-35
; hemagglutinin [HA]-tagged hPNPase
old-35
 
expression driven by the CMV promoter), or Ad.PEG-hPNPase (Ad.PEG-hPNPase
old-35
; 
HA-tagged hPNPase
old-35
 expression driven by the PEG-3 promoter) at the indicated 
MOIs, and probed 48 h postinfection for hPNPase
old-35
 expression by Western blot 
analysis using an anti-HA antibody. Expression of EF1α is shown as loading control. 
 
Figure 3. Effect of Ad.vec, Ad.CMV-hPNPase
old-35
, and Ad.PEG-hPNPase
old-35
 on 
growth and viability of FM-516-SV human melanocytes and neuroblastoma cells. 
Exponentially growing cells were untreated or infected with Ad.vec, Ad.CMV-hPNPase 
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(Ad.CMV-hPNPase
old-35
), or Ad.PEG-hPNPase (Ad.PEG-hPNPase
old-35
) at 100 pfu/cell, 
and the number of viable cells was determined at 1, 3 and 5 days postinfection using 
MTT assay. Points represent the mean relative numbers of viable cells of three 
independent experiments, and error bars indicate standard errors of the mean. 
 
Figure 4. Effect of Ad.vec, Ad.CMV-hPNPase
old-35
, and Ad.PEG-hPNPase
old-35
 on cell 
cycle distribution and hypodiploid DNA content of human neuroblastoma cells. NGP (A), 
SK-N-SH (B), and SHEP (C) cells were untreated or infected with Ad.vec, Ad.CMV-
hPNPase (Ad.CMV-hPNPase
old-35
), or Ad.PEG-hPNPase (Ad.PEG-hPNPase
old-35
) at 100 
pfu/cell, harvested at 2, 3, 4 and 5 days postinfection, and monitored for DNA content by 
propidium iodide staining and flow cytometric analysis. Columns represent the mean cell 
cycle and apoptotic fractions of three different experiments, and error bars correspond to 
standard errors of the mean. 
 
Figure 5. Effect of Ad.vec, Ad.CMV-hPNPase
old-35
, and Ad.PEG-hPNPase
old-35
 on 
caspase-3 and caspase-7 activity in human neuroblastoma cells. NGP, SK-N-SH, and 
SHEP cells were untreated or infected with Ad.vec, Ad.CMV-hPNPase (Ad.CMV-
hPNPase
old-35
), or Ad.PEG-hPNPase (Ad.PEG-hPNPase
old-35
) at 100 pfu/cell, and the 
combined activity of caspase-3 and caspase-7, relative to uninfected cells, was 
determined at 2 and 3 days postinfection. Columns represent the mean caspase-3 and 
caspase-7 activity values of triplicate wells, and error bars correspond to standard 
deviations. 
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Figure 6. Adenoviral infection induces neuronal differentiation of NGP human 
neuroblastoma cells. A: Phase-contrast images of NGP cells left untreated for five days 
(left) and five days after infection with Ad.vec (right). Adenoviral infection induced clear 
morphogical signs of neuronal differentiation, including a polar morphology and 
extensive outgrowth of neuritic processes, which formed a netlike arrangement. Similar 
morphological changes were observed after infection of NGP cells with Ad.CMV-
hPNPase
old-35
 or Ad.PEG-hPNPase
old-35
 (not shown). B: Real-time quantitative RT-PCR 
analysis of expression of neuronal differentiation markers (NEFH, NEFL, NEFM, and 
CHAT) in NGP cells harvested five days after exposure to control conditions or to 
infection with Ad.vec, Ad.CMV-hPNPase (Ad.CMV-hPNPase
old-35
), or Ad.PEG-
hPNPase (Ad.PEG-hPNPase
old-35
) at 100 pfu/cell. Columns represent the mean mRNA 
expression levels derived from two RT-PCR measurements, and error bars indicate 
standard deviations. 
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Table 1. Expression of coxsackie-adenovirus receptors (CAR) on the surface of DU-145 
prostate carcinoma cells, FM-516-SV immortalized melanocytes, and neuroblastoma 
cells 
 
 DU-145 FM-516-SV IMR-32 NGP SHEP SK-N-BE(2c) SK-N-SH 
D value 0.88 0.42 0.68 0.79 0.53 0.33 0.54 
Peak shift 4.66 0.61 1.72 1.34 1.30 0.74 1.23 
Cells were incubated with mouse monoclonal anti-CAR antibody, washed, stained with FITC-labeled anti-mouse immunoglobulins, 
washed, analyzed by flow cytometry, and compared with a number of appropriate controls, as described in Material and Methods. The 
D value, calculated by the Kolmogorov-Smirnov two-sample test for analysis of flow cytometric histograms and reflecting the greatest 
difference between the cumulative distribution functions derived from the histograms (Young, 1977), indicated for all cell types in this 
study the presence of CAR surface expression at the 99.9% confidence level. The peak shift, computed as a ratio (PCAR – Pctrl)/Pctrl 
with PCAR and Pctrl being the median of the fluorescent peak of the flow cytometric histogram of the CAR-stained cells and of the 
control cells with the highest FITC signal intensity, respectively, allows for comparison of surface CAR number and availability 
between different cell types. 
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